A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
The faecal immunochemical test (FIT) detects small amounts of blood in poo, which can be a sign of bowel cancer. Bowel cancer is the second biggest cancer killer in the UK, affecting the large bowel ...
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma in adults. This ...
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...
We have moved Health technology evaluation 20 to become HealthTech guidance 739. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people. The recommendations also apply to biosimilar ...
This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after ...
Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil)
This evidence summary has been updated and replaced by reducing sexually transmitted infections ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results